Basic Research in Cardiology

, Volume 105, Issue 4, pp 557–567 | Cite as

Lack of evidence for a pathogenic role of proteasome-directed autoimmunity in dilated cardiomyopathy

  • Antje Voigt
  • Christiane Trimpert
  • Katrin Bartel
  • Karl Egerer
  • Ulrike Kuckelkorn
  • Eugen Feist
  • Christine Gericke
  • Karin Klingel
  • Reinhard Kandolf
  • Stephan B. Felix
  • Gert Baumann
  • Peter-M. Kloetzel
  • Karl Stangl
  • Alexander Staudt
Original Contribution


The proteasome has been identified as a target of the humoral autoimmune response in different inflammatory disease entities including dilated cardiomyopathy (DCM). However, the role of proteasome autoantibodies (ProtAb) remains to be studied. Here, we have isolated human ProtAb by affinity-purification from the IgG fractions obtained from DCM patients, which predominantly detected the outer ring subunits α3 of the 20S proteasome. In an attempt to study the cellular effects potentially exerted by these ProtAb, simultaneous calcium and cell contractility measurements were performed in rat cardiomyocytes revealing no short-term effects upon human ProtAb exposure. Immunofluorescence staining and FACS analysis pointed towards a failure of human ProtAb to bind to the intact cell membrane, whereas human ProtAb detected 20S proteasomes in the cytoplasm and nucleus. The lack of the cell surface interaction of human ProtAb was in agreement with the failure of these autoantibodies to interfere with the cellular viability. Further, we investigated whether the removal of ProtAb by immunoadsorption (IA) resulted in functional improvement in DCM patients. IA was performed in 90 DCM patients (left ventricular ejection fraction ≤45%, ProtAb detection at baseline in 30% of these DCM patients). Improvement of LVEF was not associated with the initial detection and removal of ProtAb in DCM patients. ProtAb were reconstituted to baseline levels as soon as after 3 months post-IA/IgG treatment despite the overall improvement of LVEF in this study group. In conclusion, our data argue against a direct impact of ProtAb in the pathogenesis of DCM.


Cardiomyopathy Proteasome Immunoadsorption Autoimmunity 



This study was supported by the Deutsche Forschungsgemeinschaft SFB/TR 19: TP B3 to AV, UK, PMK; TP C2 to AS and SF; TP Z4 to KK and TP B5 to RK as well as by the Deutsche Forschungsgemeinschaft FE 470/3-1 to EF.

Conflict of interest statement

There are no financial conflicts to declare.


  1. 1.
    Arribas J, Rodriguez ML, Forno RAD, Castano JG (1991) Autoantibodies against the multicatalytic proteinase in patients with systemic lupus-erythematosus. J Exp Med 173:423–427CrossRefPubMedGoogle Scholar
  2. 2.
    Brychcy M, Kuckelkorn U, Hausdorf G, Egerer K, Kloetzel PM, Burmester GR, Feist E (2006) Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28. Arthritis Rheum 54:2175–2183CrossRefPubMedGoogle Scholar
  3. 3.
    Bureau JP, OlinkCoux M, Brouard N, BayleJulien S, Huesca M, Herzberg M, Scherrer K (1997) Characterization of prosomes in human lymphocyte subpopulations and their presence as surface antigens. Exp Cell Res 231:50–60CrossRefPubMedGoogle Scholar
  4. 4.
    Buvall L, Bollano E, Chen J, Shultze W, Fu M (2006) Phenotype of early cardiomyopathic changes induced by active immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the human beta(1)-adrenergic receptor. Clin Exp Immunol 143:209–215CrossRefPubMedGoogle Scholar
  5. 5.
    Caforio ALP, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, Schiaffino S (1992) Identification of alpha-cardiac and beta-cardiac myosin heavy-chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85:1734–1742PubMedGoogle Scholar
  6. 6.
    Caforio AL, Tona F, Bottaro S, Vinci A, Dequal G, Daliento L, Thiene G, Iliceto S (2008) Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 41:35–45CrossRefPubMedGoogle Scholar
  7. 7.
    Colmegna I, Sainz B, Citera G, Maldonado-Cocco JA, Garry RF, Espinoza LR (2008) Anti-20S proteasome antibodies in psoriatic arthritis. J Rheum 35:674–676PubMedGoogle Scholar
  8. 8.
    Dorffel WV, Felix SB, Wallukat G, Brehme S, Bestvater K, Hofmann T, Kleber FX, Baumann G, Reinke P (1997) Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 95:1994–1997PubMedGoogle Scholar
  9. 9.
    Feist E, Brychcy M, Hausdorf G, Hoyer B, Egerer K, Dorner T, Kuckelkorn U, Burmester GR (2007) Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells. Ann Rheum Dis 66:5–11CrossRefPubMedGoogle Scholar
  10. 10.
    Feist E, Dorner T, Kuckelkorn U, Scheffler S, Burmester GR, Kloetzel PM (2000) Diagnostic importance of anti-proteasome antibodies. Int Arch Allergy Immunol 123:92–97CrossRefPubMedGoogle Scholar
  11. 11.
    Feist E, Dorner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, Burmester GR, Kloetzel PM (1996) Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 184:1313–1318CrossRefPubMedGoogle Scholar
  12. 12.
    Feist E, Kuckelkorn U, Dorner T, Donitz H, Scheffler S, Hiepe F, Kloetzel PM, Burmester GR (1999) Autoantibodies in primary Sjogren’s syndrome are directed against proteasomal subunits of the alpha and beta type. Arthritis Rheum 42:697–702CrossRefPubMedGoogle Scholar
  13. 13.
    Felix SB, Staudt A, Baumann G (2002) Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy. Eur Heart J 4:I63–I68CrossRefGoogle Scholar
  14. 14.
    Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G (2000) Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy—three-month results from a randomized study. J Am Coll Cardiol 35:1590–1598CrossRefPubMedGoogle Scholar
  15. 15.
    Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, Wallukat G, Wernecke KD, Baumann G, Stangl K (2002) Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39:646–652CrossRefPubMedGoogle Scholar
  16. 16.
    Fu MLX, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J (1996) A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin Immunol Immunopathol 80:203–207CrossRefGoogle Scholar
  17. 17.
    Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426:895–899CrossRefPubMedGoogle Scholar
  18. 18.
    Harris JR (1968) Release of a macromolecular protein component from human erythrocyte ghosts. Biochim Biophys Acta 150:534–537CrossRefPubMedGoogle Scholar
  19. 19.
    Harris JR (1969) Isolation and purification of a macromolecular protein component from human erythrocyte ghost. Biochim Biophys Acta 188:31–42PubMedGoogle Scholar
  20. 20.
    Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ (2004) Direct evidence for a beta(1)-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113:1419–1429PubMedGoogle Scholar
  21. 21.
    Jane-Wit D, Altuntas CZ, Johnson JM, Yong S, Wickley PJ, Clark P, Wang Q, Popovic ZB, Penn MS, Damron DS, Perez DM, Tuohy VK (2007) beta(1)-Adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 116:399–410CrossRefPubMedGoogle Scholar
  22. 22.
    Jiang YC, Reynolds C, Xiao C, Feng WK, Zhou ZX, Rodriguez W, Tyagi SC, Eaton JW, Saari JT, Kang YJ (2007) Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med 204:657–666CrossRefPubMedGoogle Scholar
  23. 23.
    Kaya Z, Katus HA (2010) Role of autoimmunity in dilated cardiomyopathy. Basic Res Cardiol 105:7–8CrossRefPubMedGoogle Scholar
  24. 24.
    Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118:639–648CrossRefPubMedGoogle Scholar
  25. 25.
    Kloetzel PM (2001) Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2:179–187CrossRefPubMedGoogle Scholar
  26. 26.
    Kordonouri O, Meyer K, Egerer K, Hartmann R, Scheffler S, Burmester SSGR, Kuckelhorn U (2004) Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis. J Pediatr Endocrinol Metab 17:975–981PubMedGoogle Scholar
  27. 27.
    Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111:887–893CrossRefPubMedGoogle Scholar
  28. 28.
    Landsberger M, Staudt A, Choudhury S, Trimpert C, Herda LR, Klingel K, Kandolf R, Schultheiss HP, Kroemer HK, Volker U, Felix SB (2008) Potential role of antibodies against cardiac Kv channel-interacting protein 2 in dilated cardiomyopathy. Am Heart J 156:92–99CrossRefPubMedGoogle Scholar
  29. 29.
    Liu JH, Mao WK, Iwai CK, Fukuoka S, Vulapalli R, Huang HL, Wang TC, Sharma VK, Sheu SS, Fu M, Liang CS (2008) Adoptive passive transfer of rabbit beta(1)-adrenoceptor peptide immune cardiomyopathy into the Rag2(−/−) mouse: participation of the ER stress. J Mol Cell Cardiol 44:304–314PubMedGoogle Scholar
  30. 30.
    Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies—an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807–1816CrossRefPubMedGoogle Scholar
  31. 31.
    Matsui S, Fu MLX, Katsuda S, Hayase M, Yamaguchi N, Teraoka K, Kurihara T, Takekoshi N, Murakami E, Hoebeke J, Hjalmarson A (1997) Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 29:641–655CrossRefPubMedGoogle Scholar
  32. 32.
    Matsui S, Larsson L, Hayase M, Katsuda S, Teraoka K, Kurihara T, Murano H, Nishikawa K, Fu M (2006) Specific removal of beta 1-adrenoceptor autoantibodies by immunoabsorption in rabbits with autoimmune cardiomyopathy improved cardiac structure and function. J Mol Cell Cardiol 41:78–85CrossRefPubMedGoogle Scholar
  33. 33.
    Mayo I, Arribas J, Villoslada P, DoForno RA, Rodriguez-Vilarino S, Montalban X, de Sagarra MR, Castano JG (2002) The proteasome is a major autoantigen in multiple sclerosis. Brain 125:2658–2667CrossRefPubMedGoogle Scholar
  34. 34.
    Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R (2000) Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101:385–391PubMedGoogle Scholar
  35. 35.
    Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322CrossRefPubMedGoogle Scholar
  36. 36.
    Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477–1483CrossRefPubMedGoogle Scholar
  37. 37.
    Rivett AJ, Palmer A, Knecht E (1992) Electron-microscopic localization of the multicatalytic proteinase complex in rat-liver and in cultured-cells. J Histochem Cytochem 40:1165–1172PubMedGoogle Scholar
  38. 38.
    Schultheiss HP, Kuhl U, Janda I, Melzner B, Ulrich G, Morad M (1988) Antibody-mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 168:2105–2119CrossRefPubMedGoogle Scholar
  39. 39.
    Sixt SU, Dahlmann B (2008) Extracellular, circulating proteasomes and ubiquitin—incidence and relevance. Biochim Biophys Acta 1782:817–823PubMedGoogle Scholar
  40. 40.
    Staudt A, Böhm M, Knebel F, Staudt Y, Bischoff C, Hummel A, Borges A, Wallukat G, Delbruck M, Baumann G, Felix SB (2002) Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients suffering from dilated cardiomyopathy. Circulation 106:2448–2453CrossRefPubMedGoogle Scholar
  41. 41.
    Staudt A, Dorr M, Staudt Y, Bohm M, Probst M, Empen K, Plotz S, Maschke HE, Hummel A, Baumann G, Felix SB (2005) Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 150:729–736CrossRefPubMedGoogle Scholar
  42. 42.
    Staudt A, Eichler P, Trimpert C, Felix SB, Greinacher A (2007) Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardlomyopathy. J Am Coll Cardiol 49:1684–1692CrossRefPubMedGoogle Scholar
  43. 43.
    Staudt A, Hummel A, Ruppert J, Dorr M, Trimpert C, Birkenmeier K, Krieg T, Staudt Y, Felix SB (2006) Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J 152:712.e1–712.e6CrossRefGoogle Scholar
  44. 44.
    Staudt A, Staudt Y, Dorr M, Bohm M, Knebel F, Hummel A, Wunderle L, Tiburcy M, Wernecke KD, Baumann G, Felix SB (2004) Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol 44:829–836CrossRefPubMedGoogle Scholar
  45. 45.
    Szalay G, Meiners S, Voigt A, Lauber J, Spieth C, Speer N, Sauter M, Kuckelkorn U, Zell A, Klingel K, Stangl K, Kandolf R (2006) Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes. Am J Pathol 168:1542–1552CrossRefPubMedGoogle Scholar
  46. 46.
    Voigt A, Bartel K, Egerer K, Trimpert C, Feist E, Gericke C, Kandolf R, Klingel K, Kuckelkorn U, Stangl K, Felix SB, Baumann G, Kloetzel PM, Staudt A (2010) Humoral anti-proteasomal autoimmunity in dilated cardiomyopathy. Basic Res Cardiol 105:9–18CrossRefPubMedGoogle Scholar
  47. 47.
    Young GW, Wang YJ, Ping PP (2008) Understanding proteasome assembly and regulation: importance to cardiovascular medicine. Trends Cardiovasc Med 18:93–98CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Antje Voigt
    • 1
  • Christiane Trimpert
    • 2
  • Katrin Bartel
    • 1
  • Karl Egerer
    • 3
  • Ulrike Kuckelkorn
    • 4
  • Eugen Feist
    • 3
  • Christine Gericke
    • 5
  • Karin Klingel
    • 6
  • Reinhard Kandolf
    • 6
  • Stephan B. Felix
    • 2
  • Gert Baumann
    • 1
  • Peter-M. Kloetzel
    • 4
  • Karl Stangl
    • 1
  • Alexander Staudt
    • 2
  1. 1.Medizinische Klinik für Kardiologie und AngiologieCharité-Universitätsmedizin BerlinBerlinGermany
  2. 2.Klinik für Innere Medizin BErnst-Moritz-Arndt-UniversitätGreifswaldGermany
  3. 3.Medizinische Klinik für Rheumatologie und ImmunologieCharité-UniversitätsmedizinBerlinGermany
  4. 4.Institut für BiochemieCharité-UniversitätsmedizinBerlinGermany
  5. 5.Institut für Medizinische BiometrieCharité-UniversitätsmedizinBerlinGermany
  6. 6.Molekulare PathologieUniversität TübingenTübingenGermany

Personalised recommendations